OAKLAND,
Calif., Oct. 30, 2024 /PRNewswire/ --
The Clorox Company (NYSE: CLX) today reported results for the
first quarter of fiscal year 2025, which ended Sep. 30, 2024.
First-Quarter Fiscal Year 2025 Summary
Following is a summary of key results for the first quarter,
which reflect the lapping of the impacts of the August 2023 cyberattack and include the company's
Better Health Vitamins, Minerals and Supplements (VMS) business
through its sale date of Sept. 10,
2024. Results also reflect the prior divestiture of the
Argentina business. All
comparisons are with the first quarter of fiscal year 2024 unless
otherwise stated.
- Net sales increased 27% to $1.76
billion compared to a 20% net sales decrease in the year-ago
quarter. The increase was driven largely by higher volume
reflecting the lapping of the cyberattack. Organic
sales1 were up 31%.
- Gross margin increased 740 basis points to 45.8% from
38.4% in the year-ago quarter, primarily driven by higher volume
and cost savings.
- Diluted net earnings per share (diluted EPS) increased
371% to $0.80 from $0.17 in the year-ago quarter. The increase is
driven by strong operational performance and lapping of the
cyberattack, partially offset by a 94
cent charge from the sale of the Better Health VMS
business.
- Adjusted EPS1 increased 280% to
$1.86 from $0.49 in the year-ago quarter, primarily due to
higher net sales and cost savings, partially offset by increased
advertising investments.
- Year-to-date net cash provided by operations was
$221 million compared to $20 million in the year-ago period, representing
a 1,005% increase.
"We achieved better-than-expected results this quarter and fully
restored overall market share, enabling us to maintain our sales
outlook and raise our gross margin and EPS outlook for the year,"
said Chair and CEO Linda Rendle. "As
our consumers remain under pressure, we're focused on delivering
superior value, strong innovation and continued investment in our
brands to win with consumers and grow share. Anchored by the
strength of our portfolio and the advancement of our IGNITE
strategy, we are confident we are taking the right steps to deliver
consistent and profitable growth for the long-term."
This press release includes certain non-GAAP financial
measures. See "Non-GAAP Financial Information" at the end of this
press release for more details.
Strategic and Operational Highlights
The following are recent highlights of business and
environmental, social and governance achievements:
- Delivered double-digit organic sales growth1 across
all reportable segments, grew shares in most of its categories, and
fully restored overall market share.
- Continued to invest behind value superiority with strong
advertising, merchandising and platform-expanding innovations
including Clorox Scentiva Bleach Lavender & Jasmine,
plant-based Clorox EcoClean Disinfecting Wipes and more durable
Glad ForceFlex MaxStrength trash bags.
- Achieved the eighth consecutive quarter of gross margin
expansion, supported by another strong quarter of cost savings, and
is on track to fully rebuild gross margin in fiscal year 2025.
- Completed the Better Health VMS divestiture, following on the
prior sale of the Argentina
business, to continue evolving the portfolio in support of the
company's goal to reduce volatility and accelerate sales growth, as
well as structurally improve its margin.
- Named a Safer Choice Partner of
the Year by the U.S. Environmental Protection Agency for the
seventh time, recognized as one of the World's Best Companies by
Time, named one of the World's Most Trustworthy Companies by
Newsweek and listed as one of America's Best Employers for Women by
Forbes.
Key Segment Results
The following is a summary of key first-quarter results by
reportable segment. In addition to strong operational performance,
first-quarter results reflect the lapping of the impacts of the
August 2023 cyberattack. All
comparisons are with the first quarter of fiscal year 2024 unless
otherwise stated.
Health and Wellness (Cleaning; Professional Products)
- Net sales increased 38%, driven by 38 points of higher volume
and 2 points of favorable mix, offset by 2 points of higher trade
promotion spending.
- Segment adjusted EBIT2 increased 126%, primarily
behind higher net sales and cost savings, partially offset by
increased advertising investments.
Household (Bags and Wraps; Cat Litter; Grilling)
- Net sales increased 38%, with 43 points of higher volume
partially offset by 5 points driven by unfavorable mix and higher
trade promotion spending.
- Segment adjusted EBIT increased 1,600%, primarily due to higher
net sales and cost savings, partially offset by higher advertising
investments.
Lifestyle (Food; Water Filtration; Natural Personal
Care)
- Net sales increased 40%, with 48 points of higher volume
partially offset by 8 points driven by unfavorable mix and higher
trade promotion spending.
- Segment adjusted EBIT increased 247%, due to higher net sales,
partially offset by higher advertising investments.
International (Sales Outside the U.S.)
- Net sales decreased 4%, mainly driven by the impact of the
Argentina divestiture and 2 points
of unfavorable foreign exchange rates. Excluding Argentina and effects of foreign exchange rate
changes, organic sales1 grew 11%, driven by 11 points of
organic volume growth.
- Segment adjusted EBIT increased 3%, due to higher volume growth
excluding Argentina, partially
offset by higher advertising investments.
Divestiture of Better Health Vitamins, Minerals and
Supplements Business
As previously disclosed on Sep. 10,
2024, the company completed the divestiture of its Better
Health VMS business in its entirety. The divested business includes
the Natural Vitality, NeoCell, Rainbow Light and RenewLife brands,
relevant trademarks and licenses, and associated manufacturing and
distribution facilities in Sunrise,
Florida. The transaction is in support of the company's
IGNITE strategy and reflects the commitment to continue evolving
its portfolio to reduce volatility and accelerate sales growth, as
well as structurally improve its margin, in service of driving more
consistent and profitable growth over time. As a result of this
transaction, the company recorded a one-time after tax charge of
$118 million during the first quarter
of fiscal year 2025.
Fiscal Year 2025 Outlook
The company is updating the following elements of its
fiscal year 2025 outlook:
- Gross margin is now expected to be up about 100 to 150 basis
points, primarily due to the benefits of holistic margin management
efforts, partially offset by cost inflation and higher trade
promotion spending. This compares to the previous expectation of
about 100 basis points.
- Fiscal year diluted EPS is now expected to be between
$5.17 and $5.42 versus previously $4.95 and $5.20, a
year over year increase of 130% to 141%, respectively, reflecting
the lapping of several one-time charges recorded in the year-ago
period.
- Adjusted EPS is now expected to be between $6.65 and $6.90
compared to the previous estimate of $6.55 and $6.80, a
year over year increase of 8% to 12%, respectively. Adjusted EPS
excludes about $0.60 of expense from
long-term strategic investments in digital capabilities and
productivity enhancements, a $0.94
charge in the first quarter from the loss on sale related to the
divestiture of the Better Health VMS business, and a $0.06 benefit from cyberattack insurance recovery
in the first quarter.
The company is confirming the following elements of its
fiscal year 2025 outlook:
- The company continues to expect net sales to be flat to down
2%. Organic sales are still expected to be up 3% to up 5%,
excluding about 2 points of negative impact from the divestiture of
the company's business in Argentina and about 3 points of negative
impact from the divestiture of the Better Health VMS business.
- Selling and administrative expenses continue to be expected to
be between 15% to 16% of net sales, which includes about 150 basis
points of impact from the company's strategic investments in
digital capabilities and productivity enhancements.
- Advertising and sales promotion spending is still expected to
be about 11% to 11.5% of net sales, reflecting the company's
ongoing commitment to invest behind its brands.
- The company's effective tax rate is still expected to be about
28%. Excluding the impact of the Better Health VMS sale, the
company expects its fiscal year adjusted effective tax rate to be
about 24%.
|
|
|
|
1 Organic
sales growth / (decrease) and adjusted EPS are non-GAAP measures.
See Non-GAAP Financial Information at the end of this press release
for reconciliations to the most comparable GAAP
measures.
|
2 Adjusted
EBIT is a non-GAAP measure. See Non-GAAP Financial Information at
the end of this press release for reconciliations to the most
comparable GAAP measures.
|
Clorox Earnings Conference Call Schedule
At approximately 4:15 p.m. ET
today, Clorox will post prepared management remarks regarding its
first quarter fiscal year 2025 results.
At 5 p.m. ET today, the company
will host a live Q&A audio webcast with Chair and CEO
Linda Rendle and Chief Financial
Officer Kevin Jacobsen to discuss
the results.
Links to the live (and archived) webcast, press release and
prepared remarks can be found at Clorox Quarterly Results.
For More Detailed Financial Information
Visit the company's Quarterly Results for the
following:
- Supplemental unaudited volume and sales growth information
- Supplemental unaudited gross margin drivers information
- Supplemental unaudited cash flow information and free cash flow
reconciliation
- Supplemental unaudited reconciliation of earnings (losses)
before interest and taxes (EBIT) and adjusted EBIT
- Supplemental unaudited reconciliation of adjusted earnings per
share (EPS) and adjusted effective tax rate (ETR)
Note: Percentage and basis-point, or point, changes noted in
this press release are calculated based on rounded
numbers, except for per-share data and the effective tax
rate.
About The Clorox Company
The Clorox Company (NYSE: CLX) champions people to be well and
thrive every single day. Its trusted brands include Brita®, Burt's
Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®,
Liquid-Plumr® and Pine-Sol® as well as international brands such as
Clorinda®, Chux® and Poett®. Headquartered in Oakland, California, since 1913, Clorox was
one of the first U.S. companies to integrate ESG into its business
reporting. In 2024 the company was ranked No. 1 on Barron's 100
Most Sustainable Companies list for the second consecutive year.
Visit thecloroxcompany.com to learn more.
CLX-F
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including, among others, statements regarding the expected
or potential impact of the company's operational disruption
stemming from a cyberattack, and any such forward-looking
statements involve risks, assumptions and uncertainties. Except for
historical information, statements about future volumes, sales,
organic sales growth, foreign currencies, costs, cost savings,
margins, earnings, earnings per share, diluted earnings per share,
foreign currency exchange rates, tax rates, cash flows, plans,
objectives, expectations, growth or profitability are
forward-looking statements based on management's estimates,
beliefs, assumptions and projections. Words such as "could," "may,"
"expects," "anticipates," "targets," "goals," "projects,"
"intends," "plans," "believes," "seeks," "estimates," "will,"
"predicts," and variations on such words, and similar expressions
that reflect our current views with respect to future events and
operational, economic and financial performance are intended to
identify such forward-looking statements. These forward-looking
statements are only predictions, subject to risks and
uncertainties, and actual results could differ materially from
those discussed. Important factors that could affect performance
and cause results to differ materially from management's
expectations, are described in the sections entitled "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" in the company's Annual Report on Form
10-K for the fiscal year ended June 30,
2024, as updated from time to time in the company's
Securities and Exchange Commission filings. These factors include,
but are not limited to: unfavorable general economic and
geopolitical conditions beyond our control, including supply chain
disruptions, labor shortages, wage pressures, rising inflation, the
interest rate environment, fuel and energy costs, foreign currency
exchange rate fluctuations, weather events or natural disasters,
disease outbreaks or pandemics, such as COVID-19, terrorism, and
unstable geopolitical conditions, including ongoing conflicts in
the Middle East and Ukraine and rising tensions between
China and Taiwan, as well as macroeconomic and
geopolitical volatility and uncertainty as a result of a number of
these and other factors, including actual and potential shifts
between the U.S. and its trading partners, especially China; the ability of the company to drive
sales growth, increase prices and market share, grow its product
categories and manage favorable product and geographic mix; the
impact of the changing retail environment, including the growth of
alternative retail channels and business models, and changing
consumer preferences; our recovery from the August 2023 cyberattack, and risks related to the
company's use of and reliance on information technology systems,
including potential and actual security breaches, cyberattacks,
privacy breaches or data breaches that result in the unauthorized
disclosure of consumer, customer, employee or company information,
business, service or operational disruptions, or that impact the
company's financial results or financial reporting, or any
resulting unfavorable outcomes, increased costs or legal
proceedings; intense competition in the company's markets;
volatility and increases in the costs of raw materials, energy,
transportation, labor and other necessary supplies or services;
risks related to supply chain issues, product shortages and
disruptions to the business, as a result of increased supply chain
dependencies due to an expanded supplier network and a reliance on
certain single-source suppliers; the ability of the company to
implement and generate cost savings and efficiencies, and
successfully implement its transformational initiatives or
strategies, including achieving anticipated benefits and cost
savings from the implementation of the streamlined operating model
and digital capabilities and productivity enhancements; the
company's ability to maintain its business reputation and the
reputation of its brands and products; dependence on key customers
and risks related to customer consolidation and ordering patterns;
the ability of the company to innovate and to develop and introduce
commercially successful products, or expand into adjacent
categories and countries; the company's ability to attract and
retain key personnel, which may continue to be impacted by
challenges in the labor market, such as increasing labor costs and
sustained labor shortages; lower revenue, increased costs or
reputational harm resulting from government actions and compliance
with regulations, or any material costs imposed by changes in
regulation; changes to our processes and procedures as a result of
our digital capabilities and productivity enhancements investment
that may result in changes to the company's internal controls over
financial reporting; the ability of the company to successfully
manage global political, legal, tax and regulatory risks, including
changes in regulatory or administrative activity; risks related to
international operations and international trade, including
changing macroeconomic conditions as a result of inflation,
volatile commodity prices and increases in raw and packaging
materials prices, labor, energy and logistics; global economic or
political instability; foreign currency fluctuations, such as
devaluations, and foreign currency exchange rate controls; changes
in governmental policies, including trade, travel or immigration
restrictions, new or additional tariffs, and price or other
controls; labor claims and civil unrest; potential operational or
supply chain disruptions from wars and military conflicts,
including ongoing conflicts in the Middle
East and Ukraine and rising
tensions between China and
Taiwan; potential negative impact
and liabilities from the use, storage and transportation of
chlorine in certain international markets where chlorine is used in
the production of bleach; widespread health emergencies, such as
COVID-19; and the possibility of nationalization, expropriation of
assets or other government action; the impact of Environmental,
Social, and Governance (ESG) issues, including those related to
climate-related transition risks, changing consumer preferences,
including the environmental impact of the Company's products and
sustainability on our sales, operating costs or reputation; the
impact of product liability claims, labor claims and other legal,
governmental or tax proceedings, including in foreign jurisdictions
and in connection with any product recalls; risks relating to
acquisitions, new ventures and divestitures, and associated costs,
including for asset impairment charges related to, among others,
intangible assets, including trademarks and goodwill; and the
ability to complete announced transactions and, if completed,
integration costs and potential contingent liabilities related to
those transactions; the accuracy of the company's estimates and
assumptions on which its financial projections, including any sales
or earnings guidance or outlook it may provide from time to time,
are based; risks related to increases in the estimated fair value
of The Procter & Gamble Company's interest in the Glad
business; risks related to our reliance on third-party service
providers, including inability to meet cost savings or
efficiencies, business or systems disruptions, and other
liabilities, including legal or regulatory risk; environmental
matters, including costs associated with the remediation and
monitoring of past contamination, and possible increases in costs
resulting from actions by relevant regulators, and the handling
and/or transportation of hazardous substances; the company's
ability to effectively utilize, assert and defend its intellectual
property rights, and any infringement or claimed infringement by
the company of third-party intellectual property rights; the effect
of the company's indebtedness and credit rating on its business
operations and financial results and the company's ability to
access capital markets and other funding sources, as well as the
cost of capital to the company; the COVID-19 pandemic and related
impacts, including on the availability of, and efficiency of the
supply, manufacturing and distribution systems for, the company's
products, including any significant disruption to such systems; on
the demand for and sales of the company's products; and on
worldwide, regional and local adverse economic conditions; the
company's ability to pay and declare dividends or repurchase its
stock in the future; the impacts of potential stockholder activism;
and risks related to any litigation associated with the exclusive
forum provision in the company's bylaws.
The company's forward-looking statements in this press release
are based on management's current views, beliefs, assumptions and
expectations regarding future events and speak only as of the date
of this press release. The company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as required by the federal securities laws.
Non-GAAP Financial Information
- This press release contains non-GAAP financial information
related to organic sales growth / (decrease), adjusted EPS,
adjusted effective tax rate ("adjusted ETR") and segment adjusted
EBIT for the first quarter of fiscal year 2025, as well as adjusted
EPS outlook and adjusted ETR outlook for fiscal year 2025. The
reasons management believes these measures are useful to investors
are described below. Certain non-GAAP financial measures may be
considered in determining incentive compensation.
- Clorox defines organic sales growth / (decrease) as GAAP net
sales growth / (decrease) excluding the effect of foreign exchange
rate changes and any acquisitions or divestitures.
- Organic sales growth/(decrease) outlook for fiscal year 2025
excludes about 2 points of negative impact from the divestiture of
the company's business in Argentina and about 3 points of negative
impact from the divestiture of the Better Health VMS business.
- Management believes that the presentation of organic sales
growth / (decrease) is useful to investors because it excludes
sales from any acquisitions and divestitures, which results in a
comparison of sales only from the businesses that the company was
operating and expects to continue to operate throughout the
relevant periods, and the company's estimate of the impact of
foreign exchange rate changes, which are difficult to predict and
out of the control of the company and management. However, organic
sales growth / (decrease) may not be the same as similar measures
provided by other companies due to potential differences in methods
of calculation or differences in which items are incorporated into
these adjustments.
- Adjusted EPS is defined as diluted earnings per share that
excludes or has otherwise been adjusted for significant items that
are nonrecurring or unusual. The income tax effect on non-GAAP
items is calculated based upon the tax laws and statutory income
tax rates applicable in the tax jurisdiction(s) of the underlying
non-GAAP adjustment.
- Adjusted ETR is defined as the effective tax rate that excludes
or that has otherwise been adjusted for significant items that are
nonrecurring or unusual.
- Adjusted EPS and adjusted ETR are supplemental information that
management uses to help evaluate the company's historical and
prospective financial performance on a consistent basis over time.
Management believes that by adjusting for certain items affecting
comparability of performance over time, such as the pension
settlement charge, incremental costs, net of insurance recoveries,
related to the August 2023
cyberattack, asset impairments, charges related to the streamlined
operating model, charges related to the digital capabilities and
productivity enhancements investment, significant losses/(gains)
related to acquisitions / divestitures and other nonrecurring or
unusual items, investors and management are able to gain additional
insight into the company's underlying operating performance on a
consistent basis over time. However, adjusted EPS and adjusted ETR
may not be the same as similar measures provided by other companies
due to potential differences in methods of calculation or
differences in which items are incorporated into these
adjustments.
- Adjusted EBIT represents earnings (losses) before income taxes
excluding interest income, interest expense and other significant
items that are nonrecurring or unusual (such as the pension
settlement charge, incremental costs, net of insurance recoveries,
related to the August 2023
cyberattack, asset impairments, charges related to the streamlined
operating model, charges related to the digital capabilities and
productivity enhancements investment, significant losses/(gains)
related to acquisitions / divestitures and other nonrecurring or
unusual items impacting comparability during the period. The
company uses this measure to assess the operating results and
performance of its segments, perform analytical comparisons,
identify strategies to improve performance, and allocate resources
to each segment. Management believes that the presentation of
adjusted EBIT excluding these items is useful to investors to
assess operating performance on a consistent basis by removing the
impact of the items that management believes do not directly
reflect the performance of each segment's underlying operations.
However, adjusted EBIT may not be the same as similar measures
provided by other companies due to potential differences in methods
of calculation or differences in which items are incorporated into
these adjustments.
- The reconciliation tables below refer to the equivalent GAAP
measures adjusted as applicable for the following items:
Divestiture of Better Health Vitamins, Minerals and
Supplements Business
As previously disclosed on Sep. 10,
2024, the company completed the divestiture of its Better
Health VMS business in its entirety. The divested business includes
the Natural Vitality, NeoCell, Rainbow Light and RenewLife brands,
relevant trademarks and licenses, and associated manufacturing and
distribution facilities in Sunrise,
Florida. The transaction is in support of the company's
IGNITE strategy and reflects the commitment to continue evolving
its portfolio to reduce volatility and accelerate sales growth, as
well as structurally improve its margin, in service of driving more
consistent and profitable growth over time. As a result of this
transaction, the company recorded a one-time after tax charge of
118 million during the first quarter of fiscal year 2025.
Due to the nature, scope and magnitude of this charge, the
company's management believes presenting this charge as an
adjustment in the non-GAAP results provides additional information
to investors about trends in the company's operations and is useful
for period over period comparisons. It also allows investors to
view underlying operating results in the same manner as they are
viewed by company management.
Cyberattack Costs
As previously disclosed, incremental costs were incurred by the
company as the result of the August
2023 cyberattack. These costs related primarily to
third-party consulting services, including IT recovery and forensic
experts and other professional services incurred to investigate and
remediate the attack, as well as incremental operating costs from
the resulting disruption to the company's business operations.
Costs associated with ongoing cybersecurity monitoring and
prevention as well as enhancement to the company's cybersecurity
program are not included within this adjustment.
In the first quarter of fiscal year 2025, the company received
$10 million of insurance recoveries
related to the cyberattack. The company does not expect to incur
significant costs related to the cyberattack in future periods.
Due to the nature, scope and magnitude of these costs, the
company's management believes presenting these costs as an
adjustment in the non-GAAP results provides additional information
to investors about trends in the company's operations and is useful
for period over period comparisons. It also allows investors to
view underlying operating results in the same manner as they are
viewed by company management.
Digital Capabilities and Productivity Enhancements
Investment
As announced in August 2021, the
company plans to invest in transformative technologies and
processes over a five-year period. This investment began in fiscal
year 2022, and includes replacement of the company's enterprise
resource planning system and transitioning to a cloud-based
platform as well as the implementation of a suite of other digital
technologies. The total incremental transformational investment is
expected to be $560 to $580 million. It is expected that these
implementations will generate efficiencies and transform the
company's operations in the areas of supply chain, digital
commerce, innovation, brand building and more over the long
term.
Of the total investment, approximately 70% is expected to
represent incremental operating costs primarily recorded within
selling and administrative expenses to be adjusted from reported
EPS for purposes of disclosing adjusted EPS through fiscal year
2026. About 70% of these operating costs are expected to be related
to the implementation of the ERP, with the remaining costs
primarily related to the implementation of complementary
technologies.
Due to the nature, scope and magnitude of this investment, these
costs are considered by management to represent incremental
transformational costs above the historical normal level of
spending for information technology to support operations. Since
these strategic investments, including incremental operating costs,
will cease at the end of the investment period, are not expected to
recur in the foreseeable future and are not considered
representative of the company's underlying operating performance,
the company's management believes presenting these costs as an
adjustment in the non-GAAP results provides additional information
to investors about trends in the company's operations and is useful
for period-over-period comparisons. It also allows investors to
view underlying operating results in the same manner as they are
viewed by company management.
The following table provides reconciliation of organic sales
growth / (decrease) (non-GAAP) to net sales growth / (decrease),
the most comparable GAAP measure:
|
Three months ended
Sep. 30, 2024
|
|
Percentage change
versus the year-ago period
|
|
Health and
Wellness
|
|
Household
|
|
Lifestyle
|
|
International
|
|
Total
Company (1)
|
Net sales growth /
(decrease) (GAAP)
|
38 %
|
|
38 %
|
|
40 %
|
|
(4) %
|
|
27 %
|
Add: Foreign
exchange
|
—
|
|
—
|
|
—
|
|
2
|
|
—
|
Add/(Subtract):
Divestitures/acquisitions (2)
|
—
|
|
—
|
|
—
|
|
13
|
|
4
|
Organic sales growth /
(decrease) (non-GAAP)
|
38 %
|
|
38 %
|
|
40 %
|
|
11 %
|
|
31 %
|
|
|
(1)
|
Total Company includes
Corporate and Other. Corporate and Other includes the results of
the Better Health VMS business through the date of
divestiture.
|
(2)
|
The divestiture impact
is calculated as net sales from the Argentina and Better Health VMS
businesses after the respective sale dates in the three month
year-ago period.
|
The following tables provide reconciliations of adjusted
diluted earnings per share (non-GAAP) to diluted earnings per
share, the most comparable GAAP measure, and adjusted effective tax
rate (non-GAAP) to effective tax rate, the most comparable GAAP
measure:
Adjusted Diluted
Earnings Per Share (EPS) and Adjusted Effective Tax Rate
(ETR)
|
|
|
|
|
(Dollars in millions
except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per
share
|
|
Effective tax
rate
|
|
|
|
|
Three months
ended
|
|
Three months
ended
|
|
|
|
|
9/30/2024
|
|
9/30/2023
|
|
%
Change
|
|
9/30/2024
|
|
9/30/2023
|
|
As reported
(GAAP)
|
|
$
0.80
|
|
$
0.17
|
|
371 %
|
|
41.8 %
|
|
14.6 %
|
|
Loss on divestiture
(1)
|
|
0.94
|
|
—
|
|
|
|
(16.8) %
|
|
—
|
|
Cyberattack costs, net
of insurance
recoveries (2)
|
|
(0.06)
|
|
0.15
|
|
|
|
0.1 %
|
|
2.8 %
|
|
Streamlined operating
model (7)
|
|
—
|
|
—
|
|
|
|
— %
|
|
—
|
|
Digital capabilities
and productivity
enhancements investment (3)
|
|
0.18
|
|
0.17
|
|
|
|
(0.1) %
|
|
3.2 %
|
|
As adjusted
(non-GAAP)
|
|
$
1.86
|
|
$
0.49
|
|
280 %
|
|
25.0 %
|
|
20.6 %
|
|
(1)
|
During the three months
ended Sep. 30, 2024, the company incurred an after tax charge
of $118 related to the divestiture of the Better Health VMS
business.
|
(2)
|
During the three months
ended Sep. 30, 2024, the company recognized approximately $10
($8 after tax) of insurance recoveries related to the cyberattack.
During the three months ended Sep. 30, 2023, the company incurred
approximately $24 ($18 after tax) of costs related to the
cyberattack. Costs related primarily to third-party consulting
services, including IT recovery and forensic experts and other
professional services incurred to investigate and remediate the
attack, as well as incremental operating costs from the resulting
disruption to the company's business
operations.
|
(3)
|
During the three months
ended Sep. 30, 2024 and 2023, the company incurred
approximately $29 ($22 after tax) and $27 ($21 after tax),
respectively, of operating expenses related to its digital
capabilities and productivity enhancements investment. The expenses
relate to the following:
|
|
|
|
|
|
Three months
ended
|
|
|
|
9/30/2024
|
|
9/30/2023
|
|
External consulting
fees (a)
|
|
$
20
|
|
$
21
|
|
IT project personnel
costs (b)
|
|
2
|
|
2
|
|
Other
(c)
|
|
7
|
|
4
|
|
Total
|
|
$
29
|
|
$
27
|
|
|
(a)
|
Comprised of
third-party consulting fees incurred to assist in the project
management and end-to-end systems integration of this
transformative investment. The company relies on consultants for
certain capabilities required for these programs that the company
does not maintain internally. These costs support the
implementation of these programs incremental to the company's
normal IT costs and will not be incurred following
implementation.
|
(b)
|
Comprised of labor
costs associated with internal IT project management teams that are
utilized to oversee the new system implementations. Given the
magnitude and transformative nature of the implementations planned,
the necessary project management costs are incremental to the
historical levels of spend and will no longer be incurred
subsequent to implementation. As a result of this long-term
strategic investment, the company considers these costs not
reflective of the ongoing costs to operate its business.
|
(c)
|
Comprised of various
other expenses associated with the company's new system
implementations, including company personnel dedicated to the
project that have been backfilled with either permanent or
temporary resources in positions that are considered part of normal
operating expenses.
|
|
|
|
|
|
Full year 2025
outlook (estimated range)
|
|
|
|
|
Diluted earnings per
share
|
|
Effective Tax
Rate
|
|
|
|
|
Low
|
|
High
|
|
Midpoint
|
|
As estimated
(GAAP)
|
|
$
5.17
|
|
$
5.42
|
|
28 %
|
|
Loss on
divestiture
|
|
0.94
|
|
0.94
|
|
(4) %
|
|
Cyberattack costs, net
of insurance
recoveries
|
|
(0.06)
|
|
(0.06)
|
|
—
|
|
Digital capabilities
and productivity
enhancements investment (4)
|
|
0.60
|
|
0.60
|
|
—
|
|
As adjusted
(non-GAAP)
|
|
$
6.65
|
|
$
6.90
|
|
24 %
|
|
|
(4)
|
In fiscal year 2025,
the company expects to incur approximately $90-$100 ($68-$76 after
tax) of operating expenses related to its digital capabilities and
productivity enhancements investment.
|
The following table provides reconciliation of adjusted EBIT
(non-GAAP) to earnings before income taxes, the most comparable
GAAP measure:
|
Reconciliation of
earnings
before income taxes to
adjusted EBIT
|
|
Three months
ended
|
|
9/30/2024
|
|
9/30/2023
|
Earnings before income
taxes
|
$
177
|
|
$
29
|
Interest
income
|
(3)
|
|
(10)
|
Interest
expense
|
21
|
|
21
|
Loss on
divestiture
|
118
|
|
—
|
Cyberattack costs, net
of insurance recoveries
|
(10)
|
|
24
|
Digital capabilities
and productivity enhancements investment
|
29
|
|
27
|
Adjusted
EBIT
|
$
332
|
|
$
91
|
Condensed
Consolidated Statements of Earnings (Unaudited)
|
Dollars in millions,
except per share data
|
|
|
|
Three months
ended
|
|
|
|
09/30/2024
|
|
09/30/2023
|
Net sales
|
|
$
1,762
|
|
$
1,386
|
Cost of products
sold
|
|
955
|
|
854
|
Gross profit
|
|
807
|
|
532
|
Selling and
administrative expenses
|
|
281
|
|
276
|
Advertising
costs
|
|
201
|
|
165
|
Research and
development costs
|
|
31
|
|
29
|
Loss on
divestiture
|
|
118
|
|
—
|
Interest
expense
|
|
21
|
|
21
|
Other (income) expense,
net
|
|
(22)
|
|
12
|
Earnings before income
taxes
|
|
177
|
|
29
|
Income tax
expense
|
|
74
|
|
4
|
Net earnings
|
103
|
|
25
|
Less: Net earnings
attributable to noncontrolling interests
|
|
4
|
|
3
|
Net earnings
attributable to Clorox
|
|
$
99
|
|
$
22
|
|
|
|
|
|
Net earnings per share
attributable to Clorox
|
|
|
|
Basic net earnings per
share
|
|
$
0.80
|
|
$
0.17
|
Diluted net earnings
per share
|
|
$
0.80
|
|
$
0.17
|
|
|
|
|
|
Weighted average shares
outstanding (in thousands)
|
|
|
|
|
Basic
|
|
123,795
|
|
123,973
|
Diluted
|
|
124,677
|
|
124,650
|
Reportable Segment
Information
|
|
|
(Unaudited)
|
|
|
|
|
|
Dollars in
millions
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
sales
|
|
Three months
ended
|
|
9/30/2024
|
|
9/30/2023
|
|
% Change(1)
|
Health and
Wellness
|
$
698
|
|
$
504
|
|
38 %
|
Household
|
447
|
|
325
|
|
38
|
Lifestyle
|
320
|
|
229
|
|
40
|
International
|
259
|
|
270
|
|
(4)
|
Reportable segment
total
|
1,724
|
|
1,328
|
|
|
Corporate and Other
(2)
|
38
|
|
58
|
|
(34)
|
Total
|
$
1,762
|
|
$
1,386
|
|
27 %
|
|
|
|
|
|
|
|
Segment adjusted
EBIT
|
|
Three months
ended
|
|
9/30/2024
|
|
9/30/2023
|
|
% Change(1)
|
Health and
Wellness
|
$
235
|
|
$
104
|
|
126 %
|
Household
|
60
|
|
(4)
|
|
1,600
|
Lifestyle
|
66
|
|
19
|
|
247
|
International
|
35
|
|
34
|
|
3
|
Reportable segment
total
|
396
|
|
153
|
|
|
Corporate and Other
(2)
|
(64)
|
|
(62)
|
|
(3)
|
Total
|
$
332
|
|
$
91
|
|
265 %
|
Interest
income
|
3
|
|
10
|
|
|
Interest
expense
|
(21)
|
|
(21)
|
|
|
Loss on divestiture
(3)
|
(118)
|
|
—
|
|
|
Cyberattack costs, net
of insurance recoveries (4)
|
10
|
|
(24)
|
|
|
Digital capabilities
and productivity enhancements investment (5)
|
(29)
|
|
(27)
|
|
|
Earnings before income
taxes
|
$
177
|
|
$
29
|
|
510 %
|
|
|
|
|
|
|
|
(1)
|
Percentages based on
rounded numbers.
|
(2)
|
Corporate and Other
includes the Better Health VMS business.
|
(3)
|
Represents the loss on
divestiture of the Better Health VMS business of $118 for the three
months ended Sep. 30, 2024.
|
(4)
|
Represents cyberattack insurance recoveries of
$10 ($8 after tax) for the three months ended Sep. 30, 2024, and
incremental costs of $24 ($18 after tax) for the three months ended
Sep. 30, 2023.
|
(5)
|
Represents expenses
related to the company's digital capabilities and productivity
enhancements investment of $29 ($22 after tax) and $27 ($21 after
tax) for the three months ended Sep. 30, 2024 and 2023,
respectively.
|
Condensed
Consolidated Balance Sheets
|
|
|
|
|
|
|
|
Dollars in
millions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9/30/2024
|
|
6/30/2024
|
|
9/30/2023
|
|
|
|
|
(Unaudited)
|
|
|
|
|
(Unaudited)
|
ASSETS
|
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
278
|
|
$
|
202
|
|
$
|
518
|
|
Receivables,
net
|
|
|
595
|
|
|
695
|
|
|
581
|
|
Inventories,
net
|
|
|
594
|
|
|
637
|
|
|
710
|
|
Prepaid expenses and
other current assets
|
|
|
109
|
|
|
88
|
|
|
102
|
|
|
Total current
assets
|
|
|
1,576
|
|
|
1,622
|
|
|
1,911
|
Property, plant and
equipment, net
|
|
|
1,242
|
|
|
1,315
|
|
|
1,317
|
Operating lease
right-of-use assets
|
|
|
341
|
|
|
360
|
|
|
328
|
Goodwill
|
|
|
1,233
|
|
|
1,228
|
|
|
1,246
|
Trademarks,
net
|
|
|
503
|
|
|
538
|
|
|
541
|
Other intangible
assets, net
|
|
|
78
|
|
|
143
|
|
|
162
|
Other assets
|
|
|
524
|
|
|
545
|
|
|
486
|
Total assets
|
|
$
|
5,497
|
|
$
|
5,751
|
|
$
|
5,991
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
|
|
Notes and loans
payable
|
|
$
|
4
|
|
$
|
4
|
|
$
|
347
|
|
Current operating lease
liabilities
|
|
|
83
|
|
|
84
|
|
|
88
|
|
Accounts payable and
accrued liabilities
|
|
|
1,472
|
|
|
1,486
|
|
|
1,678
|
|
Income Taxes
Payable
|
|
|
20
|
|
|
—
|
|
|
115
|
|
|
Total current
liabilities
|
|
|
1,579
|
|
|
1,574
|
|
|
2,228
|
Long-term
debt
|
|
|
2,482
|
|
|
2,481
|
|
|
2,478
|
Long-term operating
lease liabilities
|
|
|
315
|
|
|
334
|
|
|
290
|
Other
liabilities
|
|
|
874
|
|
|
848
|
|
|
837
|
Deferred income
taxes
|
|
|
23
|
|
|
22
|
|
|
27
|
|
|
Total
liabilities
|
|
|
5,273
|
|
|
5,259
|
|
|
5,860
|
Commitments and
contingencies
|
|
|
|
|
|
|
|
|
|
Stockholders'
equity
|
|
|
|
|
|
|
|
|
|
Preferred
stock
|
|
|
—
|
|
|
—
|
|
|
—
|
Common stock
|
|
|
131
|
|
|
131
|
|
|
131
|
Additional paid-in
capital
|
|
|
1,297
|
|
|
1,288
|
|
|
1,246
|
Retained
earnings
|
|
|
31
|
|
|
250
|
|
|
299
|
Treasury
stock
|
|
|
(1,252)
|
|
|
(1,186)
|
|
|
(1,219)
|
Accumulated other
comprehensive net (loss) income
|
|
|
(147)
|
|
|
(155)
|
|
|
(494)
|
|
|
Total Clorox
stockholders' equity (deficit)
|
|
|
60
|
|
|
328
|
|
|
(37)
|
Noncontrolling
interests
|
|
|
164
|
|
|
164
|
|
|
168
|
Total stockholders'
equity
|
|
|
224
|
|
|
492
|
|
|
131
|
Total liabilities and
stockholders' equity
|
|
$
|
5,497
|
|
$
|
5,751
|
|
$
|
5,991
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/clorox-reports-q1-fiscal-year-2025-results-updates-outlook-302291742.html
SOURCE The Clorox Company